NCT Number: NCT02484404
Phase: Phase 1|Phase 2
Trial Summary: Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Acronym:
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can…
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives